Tirzepatide
Evidence: A/D — Established Human EvidenceMetabolic / Weight Management
Evidence Snapshot
What this grade covers
A for FDA-approved indications and large randomized human evidence supporting type 2 diabetes, chronic weight management, and obesity-associated obstructive sleep apnea; D for anti-aging, general wellness, performance enhancement, unrelated investigational uses, and claims extending beyond the approved products, studied populations, or documented outcomes.
Regulatory Context
FDA-approved (as Mounjaro) for type 2 diabetes and (as Zepbound) for chronic weight management and moderate-to-severe obstructive sleep apnea with obesity; other uses remain off-label.
Research Takeaway
Dual agonist at GIP and GLP-1 receptors, with preclinical work showing a biased receptor-engagement profile proposed to explain its efficacy relative to GLP-1-only agonists.
See all 5 evidence claims →Quick Summary
Tirzepatide is a dual GIP/GLP-1 receptor agonist approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity. Large phase 3 programs, including SURMOUNT and SURPASS, support its approved metabolic indications.
Mechanism & Research Overview
Dual agonist at GIP and GLP-1 receptors; preclinical work shows an 'imbalanced,' biased receptor-engagement profile - greater GIP engagement plus GLP-1 signaling biased toward cAMP production over beta-arrestin recruitment - proposed as the mechanistic basis for its efficacy relative to GLP-1-only agonists.
Evidence Grade Breakdown
A single letter grade can't capture how evidence quality differs across approved use, off-label use, and unsupported claims. The categories below break that down -- none of them grade this compound "overall."
Overall Research Grade
Tirzepatide has strong randomized human evidence and FDA approval for specific metabolic indications under the Mounjaro and Zepbound labels. The same evidence does not support unrelated anti-aging, performance, general wellness, or broad investigational claims. Safety interpretation must retain product-label warnings, studied-population boundaries, and the distinction between randomized trials, extension analyses, and pharmacovigilance reports.
AApproved Clinical Indications
Show detail
Approved Clinical Indications
FDA approval and large phase 3 programs support tirzepatide for type 2 diabetes under the Mounjaro label and for chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity under the Zepbound label.
ADirect Human Clinical Evidence
Show detail
Direct Human Clinical Evidence
Large randomized SURMOUNT and SURPASS trials provide direct human evidence for weight reduction and glycemic outcomes in their studied metabolic populations. The longer-term diabetes-prevention publication extends SURMOUNT-1 follow-up but is not counted as an independent randomized trial.
BSafety and Tolerability Evidence
Show detail
Safety and Tolerability Evidence
Randomized trials and pharmacovigilance data characterize common gastrointestinal effects, injection-site reactions, and medication-error reports. FDA prescribing information also carries a boxed thyroid C-cell tumor warning based on rodent findings, with human relevance unknown, and identifies product-specific contraindications.
BMechanism and Pharmacology
Show detail
Mechanism and Pharmacology
Preclinical receptor and pancreatic-islet work supports dual GIP and GLP-1 receptor activity and proposed biased signaling mechanisms. Mechanistic findings do not independently establish clinical outcomes beyond the human trials.
DInvestigational and Off-Label Outcomes
Show detail
Investigational and Off-Label Outcomes
The reviewed graph does not establish cardiovascular-outcomes, MASH, unrelated endocrine, neurologic, longevity, or other investigational benefits beyond the approved indications and specifically documented trial outcomes.
DBiohacking, Performance, and Wellness Claims
Show detail
Biohacking, Performance, and Wellness Claims
The reviewed evidence does not establish tirzepatide as an anti-aging, performance-enhancing, physique-preservation, or general wellness intervention outside approved medical indications and studied clinical populations.
Evidence reviewed
Direct tirzepatide evidence covering approved type 2 diabetes, chronic weight-management, and obstructive-sleep-apnea indications; phase 3 SURMOUNT and SURPASS trials; longer-term SURMOUNT-1 extension findings; pharmacovigilance; mechanism evidence; systematic review and meta-analysis; and FDA approval and prescribing-information records.
- Randomized human trials
- 3
- Observational human studies
- 1
- Systematic reviews
- 1
- Meta-analyses
- 1
- Regulatory documents
- 3
- Preclinical studies
- 1
- Primary sources reviewed
- 9 of 10
Study counts describe the reviewed evidence base. They do not independently determine evidence quality.
How MitoCore grades evidence
Grade definitions
- A
- Strong and directly applicable evidence, generally including regulatory support or multiple high-quality replicated human trials for the exact claim and population.
- A-
- Strong human evidence with limited uncertainty, narrower applicability, or incomplete replication.
- B+
- Moderately strong evidence with meaningful human support but important scope, duration, safety, or generalizability limitations.
- B
- Credible evidence with notable uncertainty, limited replication, or mixed results.
- C
- Preliminary or inconsistent evidence, usually limited human data or strong indirect evidence.
- D
- Weak, indirect, population-limited, or largely unsupported evidence for the specific use being graded.
- F
- No credible supporting evidence, evidence contradicting the claim, or claims based primarily on speculation or marketing.
Confidence definitions
- High
- The evidence classification is unlikely to change substantially with ordinary additional research.
- Moderate
- The classification is reasonably supported but could change with additional high-quality evidence.
- Low
- The evidence base is sparse, indirect, inconsistent, or dependent on uncertain assumptions.
- Very Low
- The evidence base is extremely limited, speculative, or unsuitable for firm conclusions.
Scope
The grade evaluates the evidence supporting the specific category or claim. A grade does not evaluate product purity, supplier quality, personal suitability, treatment appropriateness, individual outcomes, legality, or medical safety for a specific person.
These grades and confidence levels describe the research evidence itself. They are not medical recommendations, and they do not evaluate any specific product, supplier, or individual's situation.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Dual agonist at GIP and GLP-1 receptors, with preclinical work showing a biased receptor-engagement profile proposed to explain its efficacy relative to GLP-1-only agonists.
Sources: Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Supported
In SURMOUNT-1, tirzepatide produced dose-dependent weight reduction of 16.0-22.5% versus placebo over 72 weeks in adults with obesity.
Sources: Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
Supported
In SURMOUNT-2, tirzepatide produced significant weight reduction in adults with obesity or overweight and type 2 diabetes. Glycemic benefit is established for tirzepatide in type 2 diabetes through the separate SURPASS clinical program.
Sources: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2); Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Supported
A FAERS analysis of 65,974 real-world adverse-event reports found dosing errors and injection-site reactions as the leading real-world safety-report categories.
Sources: Real-World Safety Concerns of Tirzepatide: A Retrospective Analysis of FAERS Data (2022-2025)
Supported
Tirzepatide is FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and moderate-to-severe obstructive sleep apnea with obesity.
Sources: FDA Approval of Mounjaro (Tirzepatide), NDA 215866; FDA Approval of Zepbound for Chronic Weight Management (Tirzepatide), NDA 217806; FDA Approval of Zepbound for Obstructive Sleep Apnea (Tirzepatide), NDA 217806/S-013
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Higher-Priority Safety Consideration
Mounjaro and Zepbound prescribing information carries a boxed warning because tirzepatide caused thyroid C-cell tumors in rats. It is unknown whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans. The products are contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with Multiple Endocrine Neoplasia syndrome type 2.Safety Consideration
Gastrointestinal effects such as nausea, vomiting, and diarrhea are the most common adverse events across the SURMOUNT-1 and SURMOUNT-2 trials.Safety Consideration
Dosing errors and injection-site reactions are the top two real-world safety-report categories per a FAERS analysis of 65,974 reports (2022-2025), both rising sharply from 2022 to 2024.
Research Areas Being Studied
Research areas discussed on this page reflect the Metabolic / Weight Management category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Real-World Safety Concerns of Tirzepatide: A Retrospective Analysis of FAERS Data (2022-2025) (2025):
- Tirzepatide for Obesity Treatment and Diabetes Prevention (2024):
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) (2023):
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) (2022):
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (2021):
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Real-World Safety Concerns of Tirzepatide: A Retrospective Analysis of FAERS Data (2022-2025) | 2025 | 65,974 FDA FAERS adverse-event reports | Dosing errors (19,461 reports, 8x increase 2022-2024) and injection-site reactions (19,334 reports) were the top real-world safety signals; GI events 18,018 reports. | ||
| Tirzepatide for Obesity Treatment and Diabetes Prevention | 2024 | Subset of SURMOUNT-1 participants with obesity + prediabetes | Sustained weight reduction and markedly lower progression to type 2 diabetes vs. placebo.
| ||
| Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) | 2023 | Adults with obesity/overweight and type 2 diabetes | Mean weight reduction 13.4% (10 mg) / 15.7% (15 mg) vs. 3.3% placebo; GI-predominant adverse events, safety profile similar to other incretin therapies.
| ||
| Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) | 2022 | Adults with obesity/overweight, no diabetes (n=2539) | Mean weight reduction of 16.0-22.5% vs. placebo, dose-dependent.
| ||
| Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes | 2021 | Adults with type 2 diabetes inadequately controlled with metformin | In the SURPASS-2 randomized phase 3 trial in adults with type 2 diabetes inadequately controlled with metformin, tirzepatide produced greater reductions in glycated hemoglobin and body weight than semaglutide 1 mg at 40 weeks. This supports type 2 diabetes efficacy within the studied population and regimen but does not establish benefits for unrelated wellness or investigational uses.
| The trial supports product-specific human efficacy and short-term safety assessment in type 2 diabetes. Adverse-event and discontinuation findings must be interpreted within the studied population, comparator, doses, and duration. |
Animal / Cell / Preclinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist | 2020 | HEK293/CHO-K1 cell lines; mouse pancreatic islets (wild-type and beta-arrestin1-deficient) | Tirzepatide shows biased/imbalanced receptor engagement proposed to explain superior metabolic efficacy vs. selective GLP-1 agonists. |
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| FDA Approval of Zepbound for Obstructive Sleep Apnea (Tirzepatide), NDA 217806/S-013 | 2024 | N/A — regulatory approval letter | FDA approved supplement 217806/S-013 for Zepbound (tirzepatide) on December 20, 2024, for moderate-to-severe obstructive sleep apnea in adults with obesity, together with a reduced-calorie diet and increased physical activity. | FDA prescribing information carries a boxed warning that tirzepatide caused thyroid C-cell tumors in rats; the relevance to humans is unknown. The product is contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with Multiple Endocrine Neoplasia syndrome type 2. This warning does not establish that tirzepatide causes thyroid cancer in humans. | |
| FDA Approval of Zepbound for Chronic Weight Management (Tirzepatide), NDA 217806 | 2023 | N/A — regulatory approval letter | FDA approved NDA 217806 for Zepbound (tirzepatide) on November 8, 2023, for chronic weight management in adults meeting the approved labeling criteria, together with a reduced-calorie diet and increased physical activity. | FDA prescribing information carries a boxed warning that tirzepatide caused thyroid C-cell tumors in rats; the relevance to humans is unknown. The product is contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with Multiple Endocrine Neoplasia syndrome type 2. This warning does not establish that tirzepatide causes thyroid cancer in humans. | |
| FDA Approval of Mounjaro (Tirzepatide), NDA 215866 | 2022 | N/A — regulatory approval record | FDA approved NDA 215866 for Mounjaro (tirzepatide) on May 13, 2022, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. | FDA prescribing information carries a boxed warning that tirzepatide caused thyroid C-cell tumors in rats; the relevance to humans is unknown. The product is contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with Multiple Endocrine Neoplasia syndrome type 2. This warning does not establish that tirzepatide causes thyroid cancer in humans. |
Review Articles / Secondary Sources
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Weight loss efficiency and safety of tirzepatide: A Systematic review | 2023 | Systematic review and meta-analysis | Substantial weight reduction vs. placebo/other medications; GI side effects warrant monitoring. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Tirzepatide is FDA-approved under specific brand names for specific indications; this page is educational and does not describe or endorse any off-label, compounded, or unsupervised use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated 2026-07-11.
Follow research updates for Tirzepatide
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.